ReviewRecurrent miscarriage: current concepts in diagnosis and treatment
Introduction
Three or more consecutive spontaneous miscarriages with or without previous live births are defined as recurrent miscarriage (RM) and this condition affects about 1–3% of women during their reproductive years (Carrington et al., 2005). In the face of declining birth rates especially in Western Europe, there is a growing movement to offer extensive diagnostic procedures to patients suffering at least two spontaneous abortions. Primary RM refers to patients with consecutive losses and no prior successful pregnancy; secondary RM refers to losses following a live birth.
Known risk factors for RM are genetic disorders, uterine pathologies, endocrine dysfunctions, autoimmune diseases, acquired and inherited thrombophilia as well as environmental factors (Rai and Regan, 2006). Additionally, late pregnancy complications including intrauterine growth restriction (IUGR), preterm labor, and preeclampsia are associated with RM (Dolitzky et al., 2006). Still, in nearly 50% of RM patients the underlying cause remains unknown.
Normal pregnancies lead to haemostatic changes towards a procoagulatory state with an increase in concentrations of clotting factors and fibrinogen, and decreased levels of anticoagulant factors with reduced fibrinolytic activity (Brenner, 2004). It seems that a subgroup of RM patients is in a permanent “acquired” procoagulatory state as fibrin deposits are found in the intervillous space of their placentas (Rai et al., 2003). There is increasing evidence that in some RM patients, this “procoagulatory state” is linked to increased concentrations of circulating microparticles (Laude et al., 2001, Carp et al., 2004, Toth et al., 2008b, Toth, 2009).
Other possible new risk factors for RM include nuclear hormone receptors like peroxisome proliferator-activated receptors (PPAR) as well as leptin and the glycoprotein glycodelin (Toth et al., 2007, Toth et al., 2008c, Toth et al., 2009b). However, only preliminary data are available indicating a possible role of these factors in the pathophysiology of disturbed pregnancy. RM patients with acquired or inherited thrombophilia are currently treated with aspirin and/or low molecular weight heparin (LMWH), although only few placebo-controlled trials have proven their benefit concerning live birth rate in RM patients, especially in patients with antiphospholipid syndrome (APS). With regard to possible new treatment options, TNFα inhibitors and granulocyte colony-stimulating factor (G-CSF) seem to be two promising new drugs, although larger clinical trials have to be conducted to evaluate their potential benefits in the treatment of RM patients.
Section snippets
Chromosomal and single gene disorders
In 4% of couples suffering from RM, changes in the karyotypes including balanced reciprocal translocations, Robertsonian-translocations, gonosomal mosaic and inversions are found, compared to 0.2% within control couples (Franssen et al., 2005). Single gene disorders (e.g. alpha thalassemia major) can contribute to late (second and third trimester) pregnancy losses (Laurino et al., 2005). However, Stern et al. did not find any difference in incidence of abnormal karyotypes when comparing
Circulating microparticles
Circulating microparticles are increased during normal (Bretelle et al., 2003) and disturbed pregnancy conditions such as preeclampsia (Gonzalez-Quintero et al., 2004). Furthermore, there is evidence that a subgroup of RM patients is in a permanent prothrombotic state even outside pregnancy (Rai et al., 2003). Microparticles from circulating blood cells expose phosphatidylserine and thus are believed to induce coagulation (Vanwijk et al., 2003). Injection of artificial phospholipid vesicles
Summary
In developed countries, maternal age at the first pregnancy is increasing and birth rates are declining so that couples are increasingly focused on achieving one uncomplicated pregnancy. Clinicians can cope with these expectations by negotiation or by identifying any underlying problems. However, patients with miscarriages at the age of 35 years or older should seek proper diagnosis and treatment strategies even after two events. Therefore, known risk factors for RM should be excluded by
Acknowledgements
PD Dr. Bettina Toth was supported by the LMUexcellent Mentoring Program of the Ludwig-Maximilians University, Munich, Germany; by the “Friedrich Baur Scholarship” and by the “Universitätsgesellschaft” of the Ludwig-Maximilians University, Munich, Germany. U. Jeschke is supported by the Deutsche Forschungsgemeinschaft (DFG).
References (85)
- et al.
Massive perivillous fibrinoid causing recurrent placental failure
BJOG
(2003) Haemostatic changes in pregnancy
Thromb. Res.
(2004)Thrombophilia and pregnancy loss in first intended pregnancy
J. Thromb. Haemost.
(2005)- et al.
Structural analysis of the oligosaccharides derived from glycodelin, a human glycoprotein with potent immunosuppressive and contraceptive activities
J. Biol. Chem.
(1995) - et al.
A randomized study of thromboprophylaxis in women with unexplained consecutive recurrent miscarriages
Fertil. Steril.
(2006) - et al.
Levels and effects of different forms of anxiety during pregnancy after a prior miscarriage
Eur. J. Obstet. Gynecol. Reprod. Biol.
(2009) - et al.
PPARs and the placenta
Placenta
(2007) - et al.
Elevated plasma endothelial microparticles: preeclampsia versus gestational hypertension
Am. J. Obstet. Gynecol.
(2004) - et al.
Expression of placental leptin and leptin receptor transcripts in early pregnancy and at term
Obstet. Gynecol.
(1998) - et al.
Hyperprolactinemic recurrent miscarriage and results of randomized bromocriptine treatment trials
Fertil. Steril.
(1998)
Pregnancy complications in PCOS
Best Pract. Res. Clin. Endocrinol. Metab.
Polycystic ovary syndrome
Best Pract. Res. Clin. Obstet. Gynaecol.
The septate uterus: a review of management and reproductive outcome
Fertil. Steril.
Celiac disease and risk of adverse fetal outcome: a population-based cohort study
Gastroenterology
International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)
J. Thromb. Haemost.
Hysteroscopic metroplasty for septate uterus and repetitive abortions: reproductive outcome
Eur. J. Obstet. Gynecol. Reprod. Biol.
Recurrent miscarriage
Lancet
A comparative study of glycodelin concentrations in uterine flushings in women with subseptate uteri, history of unexplained recurrent miscarriage and healthy controls
Eur. J. Obstet. Gynecol. Reprod. Biol.
Etiologic factors and subsequent reproductive performance in 195 couples with a prior history of habitual abortion
Am. J. Obstet. Gynecol.
Annexin V inhibits phosphatidylserine-induced intrauterine growth restriction in mice
Placenta
Characterization of human villous and extravillous trophoblasts isolated from first trimester placenta
Lab. Invest.
Proportional change of CD4+ CD25+ regulatory T cells after lymphocyte therapy in unexplained recurrent spontaneous abortion patients
Fertil. Steril.
Overt and subclinical hypothyroidism complicating pregnancy
Thyroid
Interferon gamma contributes to initiation of uterine vascular modification, decidual integrity, and uterine natural killer cell maturation during normal murine pregnancy
J. Exp. Med.
Circulating microparticles: a marker of procoagulant state in normal pregnancy and pregnancy complicated by preeclampsia or intrauterine growth restriction
Thromb. Haemost.
Placental trophoblast and endothelial cells as target of maternal immune response
Autoimmunity
Leptin down-regulates peroxisome proliferator-activated receptor gamma (PPAR-gamma) mRNA levels in primary human monocyte-derived macrophages
Mol. Cell. Biochem.
Prevalence of circulating procoagulant microparticles in women with recurrent miscarriage: a case-controlled study
Hum. Reprod.
Recurrent miscarriage: pathophysiology and outcome
Curr. Opin. Obstet. Gynecol.
A randomized, double-blind, placebo-controlled trial of intravenous immunoglobulin in the prevention of recurrent miscarriage: evidence for a therapeutic effect in women with secondary recurrent miscarriage
Hum. Reprod.
Multifactorial etiology of recurrent miscarriage and its scientific and clinical implications
Gynecol. Obstet. Invest.
Unexplained sporadic and recurrent miscarrage in the new millennium: a critical analysis of immune mechanisms and treatments
Hum. Reprod. Update
Future pregnancy outcome in unexplained recurrent first trimester miscarriage
Hum. Reprod.
Consensus on infertility treatment related to polycystic ovary syndrome
Fertil. Steril.
A phase 3, randomized, placebo-controlled trial of filgrastim in patients with haematological malignancies undergoing matched-related allogeneic bone marrow transplantation
Arch. Drug Inf.
Influence of activating and inhibitory killer immunoglobulin-like receptors on predisposition to recurrent miscarriages
Hum. Reprod.
Selective chromosome analysis in couples with two or more miscarriages: case–control study
BMJ
Effect of leukocyte therapy on tumor necrosis factor-alpha and interferon-gamma production in patients with recurrent spontaneous abortion
Am. J. Reprod. Immunol.
Successful pregnancy outcome in women with bad obstetric history and recurrent fetal loss due to thrombophilia: effect of unfractionated heparin and low-molecular weight heparin
Clin. Appl. Thromb. Hemost.
Association of maternal killer-cell immunoglobulin-like receptors and parental HLA-C genotypes with recurrent miscarriage
Hum. Reprod.
Effects of metformin on early pregnancy loss in the polycystic ovary syndrome
J. Clin. Endocrinol. Metab.
Evidence-based guidelines for the investigation and medical treatment of recurrent miscarriage
Hum. Reprod.
Cited by (0)
- 1
Tel.: +49 89 7095 6825; fax: +49 89 7095 3844.
- 2
Tel.: +49 89 5160 4266; fax: +49 89 5160 4916.
- 3
Tel.: +49 89 24414 40; fax: +49 89 244144 41.
- 4
Tel.: +30 2810392131; fax: +30 2810392131.